RxDoctor Payments Data

Gregory Hanes, MD

Neurology · Sarasota, FLNPI 1255342994

Payments from drug & device makers

$750,665in general payments, 2019–2025

Across 903 payments — averaging $831.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$645K
  • Janssen Research & Development, LLC$92K
  • Argenx US, Inc.$3K
  • Catalyst Pharmaceuticals, Inc.$2K
  • AstraZeneca$667
  • UCB, Inc.$629
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$21,5138%
  • Speaking & faculty fees$204,71480%
  • Travel & lodging$12,5775%
  • Food & beverage$16,2996%
  • Education$400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)434$644,765
Janssen Research & Development, LLC40$91,955
Argenx US, Inc.15$3,456
Catalyst Pharmaceuticals, Inc.12$1,830
AstraZeneca(2 entities)26$667
UCB, Inc.29$629
Amgen(2 entities)19$503
Acorda Therapeutics, Inc22$498
Teva Pharmaceuticals USA, Inc.27$471
Eisai Inc.14$398
GE HealthCare15$395
Pfizer19$391
Neurocrine Biosciences, Inc.16$383
Takeda Pharmaceuticals U.S.A., Inc.12$383
Acadia Pharmaceuticals Inc13$278
SK Life Science, Inc.8$263
Alnylam Pharmaceuticals Inc.10$228
Neurelis, Inc.12$225
Sunovion Pharmaceuticals Inc.14$222
Amneal Pharmaceuticals LLC12$202
Lundbeck LLC8$196
CSL Behring7$167
Novartis21$162
Lilly USA, LLC8$156
Otsuka America Pharmaceutical, Inc.6$138
Revance Therapeutics, Inc.1$134
Kyowa Kirin, Inc.7$123
Greenwich Biosciences, Inc.6$119
Biohaven Pharmaceutical Holding Company Ltd.5$93
Adamas Pharmaceuticals, Inc.5$89
Tanabe Pharma America, Inc.3$71
Supernus Pharmaceuticals, Inc.4$66
Avanir Pharmaceuticals, Inc.4$62
Johnson & Johnson3$61
Grifols USA, LLC3$59
Biogen3$58
Biohaven Pharmaceuticals, Inc.3$57
Akcea Therapeutics, Inc.3$53
Corium, LLC2$53
MDD US Operations, LLC3$53
Ultragenyx Pharmaceutical Inc.3$47
Aucta Pharmaceuticals, Inc.2$46
Merz Pharmaceuticals, LLC2$46
Sumitomo Pharma America, Inc.2$40
Impel Pharmaceuticals LLC2$39
Avion Pharmaceuticals2$35
Amylyx Pharmaceuticals, Inc.2$34
Assertio Therapeutics, Inc.2$31
Stryker1$28
Jazz Pharmaceuticals Inc.1$28
Boston Scientific1$25
Axsome Therapeutics, Inc.1$25
Bausch Health US, LLC1$24
Azurity Pharmaceuticals, Inc.1$19
EDW Pharma, Inc.1$19
Xeris Pharmaceuticals, Inc.1$15
Zyla Life Sciences, Inc.1$15
Genentech USA, Inc.1$15
GRT US Holding, Inc.1$13
Strongbridge US Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$750,665 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$612,296
Medicare patients
1,043
Services billed
61,772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PanzygaImmun Glob G(Igg)-Ifas/Glycine36$809,936
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5017$329,150
GammakedImmune Globul G/Gly/Iga Avg 4615$253,566
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5012$163,423
Gamunex-CImmune Globul G/Gly/Iga Avg 4615$93,257
BotoxOnabotulinumtoxina27$42,787
EliquisApixaban11$6,533
Maxalt MltRizatriptan Benzoate12$4,555
Memantine Hcl30$3,376
Mycophenolate Mofetil19$2,546
Duloxetine Hcl133$1,979
Gabapentin108$1,626
Riluzole17$1,360
Propranolol Hcl ErPropranolol Hcl26$1,201
Levetiracetam36$1,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga, Eliquis$391$816,46947 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$383$329,15017 claims
CSL BehringPrivigen$167$163,42312 claims
Grifols USA, LLCGamunex-C$59$93,25715 claims
AbbVieBotox$644,765$42,78727 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$202$2,54619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.

Other neurology in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →